Shares of Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) saw unusually-high trading volume on Friday . Approximately 1,175,224 shares changed hands during mid-day trading, an increase of 480% from the previous session’s volume of 202,586 shares.The stock last traded at $1.17 and had previously closed at $0.80.
AST has been the topic of a number of recent analyst reports. Zacks Investment Research raised shares of Asterias Biotherapeutics from a “hold” rating to a “buy” rating and set a $1.50 price target on the stock in a report on Tuesday, July 10th. HC Wainwright set a $11.00 target price on shares of Asterias Biotherapeutics and gave the stock a “buy” rating in a research report on Monday, July 16th. B. Riley set a $6.00 target price on shares of Asterias Biotherapeutics and gave the stock a “buy” rating in a research report on Friday, August 3rd. Finally, Raymond James cut shares of Asterias Biotherapeutics from an “outperform” rating to a “market perform” rating in a research report on Friday, August 10th.
Asterias Biotherapeutics (NYSEAMERICAN:AST) last announced its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.10) EPS for the quarter, hitting analysts’ consensus estimates of ($0.10). Asterias Biotherapeutics had a negative net margin of 403.38% and a negative return on equity of 79.80%. The firm had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.11 million.
Asterias Biotherapeutics Company Profile (NYSEAMERICAN:AST)
Asterias Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia.
Featured Story: Liquidity
Receive News & Ratings for Asterias Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.